/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Abiraterone Acetate Tablets USP, 250 mg, a generic version of Zytiga1 Tablets, 250 mg, of Janssen Biotech, Inc.
According to IQVIA sales data for the 12 month period ending August 2019, the Zytiga Tablets, 250 mg market2 achieved annual sales of approximately $794.1 million*. Glenmark's current portfolio consists of 162 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalents
*IQVIA National Sales Perspectives: Retail & Non-Retail, August 2019
About Glenmark Pharmaceuticals
Disclaimer: No Business Standard Journalist was involved in creation of this content